North China Pharmaceutical Co Ltd Cash Flow Quality Index
North China Pharmaceutical Co Ltd cash flow quality index. North China Pharmaceutical Co Ltd (600812) has a Cash Flow Quality Index of 4.86x as of September 2025. Operating cash flow of CN¥170.24 Million exceeds net income of CN¥35.01 Million, indicating high earnings quality where cash backs reported profits. Explore 600812 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of North China Pharmaceutical Co Ltd (1998–2025)
Cash flow quality index of North China Pharmaceutical Co Ltd from 1998 to 2025. Historical Cash Flow Quality Index for North China Pharmaceutical Co Ltd across 25 annual periods. Values consistently above 1.0x indicate high-quality earnings. See how leveraged is North China Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
North China Pharmaceutical Co Ltd Cash Flow Quality Index by Year (1998–2025)
North China Pharmaceutical Co Ltd cash flow quality index by year from 1998 to 2025. Year-by-year earnings quality comparison for North China Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see North China Pharmaceutical Co Ltd cash conversion from operations.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 6.43x | CN¥1.18 Billion | CN¥183.06 Million | ▲ +12.4% |
| 2024 | 5.72x | CN¥1.23 Billion | CN¥214.97 Million | ▼ -97.3% |
| 2023 | 209.45x | CN¥1.02 Billion | CN¥4.89 Million | ▲ +605.6% |
| 2021 | 29.68x | CN¥1.05 Billion | CN¥35.38 Million | ▲ +312.3% |
| 2020 | 7.20x | CN¥752.15 Million | CN¥104.48 Million | ▲ +45.3% |
| 2019 | 4.96x | CN¥732.97 Million | CN¥147.90 Million | ▼ -6.7% |
| 2018 | 5.31x | CN¥774.33 Million | CN¥145.82 Million | ▼ -73.3% |
| 2017 | 19.90x | CN¥287.25 Million | CN¥14.44 Million | ▲ +330.0% |
| 2016 | -8.65x | CN¥-446.53 Million | CN¥51.63 Million | ▼ -459.0% |
| 2015 | 2.41x | CN¥122.50 Million | CN¥50.85 Million | ▼ -15.4% |
| 2014 | 2.85x | CN¥90.56 Million | CN¥31.79 Million | ▲ +120.0% |
| 2013 | -14.22x | CN¥-135.03 Million | CN¥9.49 Million | ▼ -212.9% |
| 2012 | -4.55x | CN¥-63.92 Million | CN¥14.06 Million | ▼ -379.5% |
| 2011 | 1.63x | CN¥227.60 Million | CN¥139.96 Million | ▲ +171.2% |
| 2010 | -2.29x | CN¥-598.35 Million | CN¥261.81 Million | ▼ -157.7% |
| 2008 | 3.96x | CN¥1.09 Billion | CN¥273.95 Million | ▼ -55.8% |
| 2007 | 8.96x | CN¥664.37 Million | CN¥74.11 Million | ▼ -14.2% |
| 2006 | 10.45x | CN¥597.12 Million | CN¥57.12 Million | ▲ +145.2% |
| 2004 | 4.26x | CN¥310.39 Million | CN¥72.81 Million | ▲ +104.1% |
| 2003 | 2.09x | CN¥580.32 Million | CN¥277.87 Million | ▼ -48.4% |
| 2002 | 4.05x | CN¥738.50 Million | CN¥182.52 Million | ▲ +116.9% |
| 2001 | 1.87x | CN¥367.28 Million | CN¥196.84 Million | ▲ +89.0% |
| 2000 | 0.99x | CN¥133.49 Million | CN¥135.24 Million | ▲ +131.8% |
| 1999 | -3.10x | CN¥-373.62 Million | CN¥120.50 Million | ▼ -13.8% |
| 1998 | -2.73x | CN¥-326.74 Million | CN¥119.90 Million | — |